NASDAQ:MLTX MoonLake Immunotherapeutics (MLTX) Stock Price, News & Analysis $46.02 +0.44 (+0.97%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$44.71▼$46.0550-Day Range$40.15▼$50.1952-Week Range$35.11▼$64.98Volume115,077 shsAverage Volume384,098 shsMarket Capitalization$2.94 billionP/E RatioN/ADividend YieldN/APrice Target$78.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MoonLake Immunotherapeutics alerts: Email Address MoonLake Immunotherapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.69 Rating ScoreUpside/Downside70.9% Upside$78.67 Price TargetShort InterestBearish14.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($1.45) to ($2.47) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.67 out of 5 starsMedical Sector833rd out of 910 stocksPharmaceutical Preparations Industry386th out of 426 stocks 3.3 Analyst's Opinion Consensus RatingMoonLake Immunotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.69, and is based on 9 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageMoonLake Immunotherapeutics has only been the subject of 4 research reports in the past 90 days.Read more about MoonLake Immunotherapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.78% of the float of MoonLake Immunotherapeutics has been sold short.Short Interest Ratio / Days to CoverMoonLake Immunotherapeutics has a short interest ratio ("days to cover") of 22.7, which indicates bearish sentiment.Change versus previous monthShort interest in MoonLake Immunotherapeutics has recently decreased by 0.13%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMoonLake Immunotherapeutics does not currently pay a dividend.Dividend GrowthMoonLake Immunotherapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MLTX. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for MLTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MoonLake Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders12.02% of the stock of MoonLake Immunotherapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.85% of the stock of MoonLake Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about MoonLake Immunotherapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MoonLake Immunotherapeutics are expected to decrease in the coming year, from ($1.45) to ($2.47) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MoonLake Immunotherapeutics is -61.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MoonLake Immunotherapeutics is -61.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMoonLake Immunotherapeutics has a P/B Ratio of 5.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about MoonLake Immunotherapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Golden CrestBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.>> Get Your FREE Wealth Protection Guide << About MoonLake Immunotherapeutics Stock (NASDAQ:MLTX)MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Read More MLTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MLTX Stock News HeadlinesAugust 28, 2024 | msn.comMoonLake Immunotherapeutics (MLTX): One of Oppenheimer's Top Stock Picks For the Next 12 MonthsAugust 28, 2024 | americanbankingnews.comMoonLake Immunotherapeutics (NASDAQ:MLTX) Stock Rating Lowered by Wolfe ResearchSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 27, 2024 | finance.yahoo.comMoonLake Immunotherapeutics (MLTX): One of Oppenheimer’s Top Stock Picks For the Next 12 MonthsAugust 27, 2024 | msn.comWolfe Research Downgrades MoonLake Immunotherapeutics (MLTX)August 26, 2024 | seekingalpha.comMoonLake Immunotherapeutics downgraded on concerns about lack of near-term catalystsAugust 22, 2024 | finance.yahoo.comWe're Interested To See How MoonLake Immunotherapeutics (NASDAQ:MLTX) Uses Its Cash Hoard To GrowAugust 17, 2024 | finance.yahoo.comMLTX Sep 2024 60.000 call (MLTX240920C00060000)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 8, 2024 | markets.businessinsider.comBuy Rating for MoonLake Immunotherapeutics Backed by Strong Prospects for Lead Candidate and Financial StabilityAugust 7, 2024 | finance.yahoo.comMoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11July 18, 2024 | seekingalpha.comMoonLake Immunotherapeutics: Second Late-Stage Program Moves Sonelokimab ForwardMay 17, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for MoonLake Immunotherapeutics Amidst Promising Clinical Trials and Strategic Development PlansMay 16, 2024 | globenewswire.comMoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativaMay 12, 2024 | seekingalpha.comMoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market ExpansionMay 10, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Buy Rating Justified by Strong Clinical Execution and Financial PositionMay 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics Earns Buy Rating: Advancing Clinical Programs and Strong Financial PositionMay 8, 2024 | markets.businessinsider.comMoonLake Immunotherapeutics’ Strong Buy Rating: Promising Clinical Developments and Significant Market PotentialSee More Headlines Receive MLTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MoonLake Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MLTX CUSIPN/A CIK1821586 Webwww.moonlaketx.com Phone41-41-510-8022FaxN/AEmployees2Year FoundedN/APrice Target and Rating Average Stock Price Target$78.67 High Stock Price Target$104.00 Low Stock Price Target$59.00 Potential Upside/Downside+70.9%Consensus RatingModerate Buy Rating Score (0-4)2.69 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($0.75) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-36,010,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-10.61% Return on Assets-10.36% Debt Debt-to-Equity RatioN/A Current Ratio43.71 Quick Ratio43.71 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.30 per share Price / Book5.54Miscellaneous Outstanding Shares63,887,000Free Float56,208,000Market Cap$2.94 billion OptionableOptionable Beta1.26 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesDr. Jorge Santos da Silva (Age 46)Co-Founder, CEO & Director Comp: $1.11MDr. Kristian Reich (Age 58)Co-Founder & Chief Scientific Officer Comp: $1.2MMr. Matthias Bodenstedt (Age 36)Chief Financial Officer Comp: $588.25kMr. Oliver DaltropChief Technical OfficerNicolas MosimannGeneral CounselLuciana MarquesDirector of HR, People & CultureMs. Nuala BrennanChief Clinical Development OfficerMore ExecutivesKey CompetitorsCipher MiningNASDAQ:CIFRDocGoNASDAQ:DCGOEdtechX Holdings Acquisition Corp. IINASDAQ:EDTXQuantum-SiNASDAQ:QSICherry Hill Mortgage InvestmentNYSE:CHMIView All CompetitorsInsiders & InstitutionsQuarry LPBought 1,900 shares on 8/16/2024Ownership: 0.005%Millennium Management LLCBought 185,789 shares on 8/15/2024Ownership: 0.340%The Manufacturers Life Insurance Company Bought 31,401 shares on 8/15/2024Ownership: 0.179%Fred Alger Management LLCSold 7,693 shares on 8/14/2024Ownership: 1.032%Squarepoint Ops LLCBought 12,500 shares on 8/14/2024Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions MLTX Stock Analysis - Frequently Asked Questions How have MLTX shares performed this year? MoonLake Immunotherapeutics' stock was trading at $60.39 at the beginning of 2024. Since then, MLTX shares have decreased by 23.8% and is now trading at $46.02. View the best growth stocks for 2024 here. How were MoonLake Immunotherapeutics' earnings last quarter? MoonLake Immunotherapeutics (NASDAQ:MLTX) announced its earnings results on Wednesday, August, 7th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.28) by $0.11. Who are MoonLake Immunotherapeutics' major shareholders? Top institutional shareholders of MoonLake Immunotherapeutics include Avoro Capital Advisors LLC (4.34%), Federated Hermes Inc. (1.77%), Marshall Wace LLP (1.72%) and Logos Global Management LP (1.17%). Insiders that own company stock include Bihua Chen, Da Silva Jorge Santos, Matthias Bodenstedt and Kristian Reich. View institutional ownership trends. How do I buy shares of MoonLake Immunotherapeutics? Shares of MLTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MLTX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
